May 8, 2020 Oncolytics Biotech® Reports 2020 First Quarter Financial Results and Operational Highlights
May 8, 2020 Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
May 4, 2020 Oncolytics Biotech® to Present Clinical Findings of Pelareorep-Induced Immune Response in Breast Tumors at the ESMO Breast Cancer Virtual Meeting
Apr 17, 2020 Oncolytics Biotech® Updates Clinical Development and Operations Activities During the COVID-19 Pandemic
Apr 2, 2020 Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer
Mar 5, 2020 Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
Feb 28, 2020 Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Year End 2019 Financial Results and Operational Highlights
Jan 27, 2020 Oncolytics Biotech® Announces Statistically Significant Data Identifying CEACAM6 as a Prospective Prognostic Biomarker for Pelareorep in the Treatment of Pancreatic Adenocarcinoma
